Royal Lee Cancer Center
A Guangzhou tertiary oncology hospital focused on MDT-led solid tumor care, minimally invasive interventions, and international patient coordination.
About Royal Lee Cancer Center
Royal Lee Cancer Center, also presented on official English pages as RoyalLee Cancer Hospital and Guangzhou Royal Lee Cancer Center, is located at No.1 Ciji Road in Sino-Singapore Guangzhou Knowledge City, Huangpu District, Guangzhou. Official pages state that the hospital was officially established on November 25, 2010, and describe it as a 3A international-platform-based oncology hospital under the management of the Guangdong Provincial Health Commission. It is described as solely funded and constructed by Royal Lee (Thailand) International Group / Royallee Group, with official pages reporting 400 beds, a large modern oncology campus, 12 clinical departments, and 7 technical departments.
Cancer care at Royal Lee Cancer Center is organized around solid tumor diagnosis, whole-process tumor management, multidisciplinary planning, and minimally invasive oncology. Official pages identify key departments and programs including the Gastrointestinal Oncology Department, Minimally Invasive Oncology Center, Gynecological Oncology Department, Breast Oncology Department, Body Surface Tumor Department, Palliative Medicine Center, Healthcare Management Center, and Royallee–Boji Renyi Hepatobiliary and Pancreatic Oncology Department. The hospital’s MDT service covers digestive, thoracic, breast and gynecologic, head and neck, and urogenital tumors, especially for newly diagnosed, recurrent, metastatic, complex, or poorly responsive cases.
Verified official material describes imaging and technical infrastructure including MRI, CT, DSA, ultrasonography, imaging, surgical anesthesia, ICU, laboratory, pharmacy, laminar-flow operating rooms, and a compound operating room. Official treatment pages and MDT content mention IRE / NanoKnife, cryosurgical ablation / argon-helium knife, Y-90 radioembolization, TACE, brachytherapy, photodynamic therapy, immunotherapy, targeted therapy, chemotherapy, hyperthermia, TCM supportive care, pain and sleep management, nutrition, and palliative medicine. The hospital’s JCI status should be treated cautiously because newer official pages claim JCI accreditation while an older official profile described JCI certification as planned.
CancerFax supports international patients and families by helping them organize medical records, prepare a concise case summary, confirm whether Royal Lee Cancer Center is appropriate for their diagnosis, and coordinate report submission or appointment requests. CancerFax is not the hospital and does not provide treatment; it serves as a patient-navigation and coordination platform so that families can compare options, understand documents needed before travel, and communicate more efficiently with the right hospital team.
| Hospital at a Glance | |
|---|---|
| Country | China |
| City | Guangzhou |
| Established | November 25, 2010 |
| Hospital Type | Tertiary oncology hospital / 3A international-platform-based oncology hospital |
| Accreditation | ⚠️ VERIFY: newer official pages claim JCI accreditation, while an older official page described JCI certification as planned |
| Beds | 400 beds |
| Annual Cancer Patients | ⚠️ VERIFY: annual cancer patient volume is not published on official English pages reviewed |
| Research Focus | Solid tumor MDT care, minimally invasive oncology, interventional oncology, and whole-process tumor management; clinical-trial activity not clearly published on official English pages reviewed |
Why Patients Choose Royal Lee Cancer Center
Royal Lee Cancer Center is most relevant for international patients seeking MDT-led solid tumor planning, minimally invasive oncology options, and coordinated travel support in Guangzhou. Its official materials emphasize whole-process tumor management, advanced interventional techniques, and multilingual patient services.
Cancer Specialties and Clinical Departments
Royal Lee Cancer Center’s oncology profile is strongest in solid tumors, MDT planning, interventional oncology, minimally invasive local treatments, and supportive care for international patients. Hematologic malignancy and pediatric oncology services were not clearly verified on official English pages reviewed, so those areas should be confirmed case by case.
Advanced Treatment Capabilities
Key Specialists at Royal Lee Cancer Center
Official materials describe Royal Lee Cancer Center as an oncology platform bringing together more than 100 oncologists from top hospitals in China and abroad. The MDT service is structured around joint review by oncology, surgery, interventional treatment, radiology, imaging, and pathology experts, with additional input from pain management, sleep management, TCM, nutrition, palliative medicine, and disease-specific tumor departments where relevant.
For international patients, the most practical route is usually to submit a complete medical record set for preliminary review or online second opinion before travel. CancerFax can help prepare the case summary, organize imaging and pathology documents, request department matching, and clarify whether the case should be directed to gastrointestinal oncology, hepatobiliary-pancreatic oncology, breast oncology, gynecologic oncology, minimally invasive oncology, palliative medicine, or another Royal Lee team.
Patients seeking specific physician consultations or second opinions may request a review through the CancerFax coordination process before confirming travel or admission.
Clinical Infrastructure and Treatment Technology
Royal Lee Cancer Center’s verified infrastructure includes a modern oncology campus with inpatient wards, technical departments, imaging, operating rooms, ICU, laboratory, pharmacy, and a solid tumor MDT platform. Claims about certain emerging cell therapies should be confirmed case by case because they were not clearly verified on official English pages reviewed.
- MRI, CT and DSA are listed in official hospital profile and FAQ material
- Ultrasonography Department and Imaging Unit Department are listed on official department pages
- Pathology review is included in the MDT service structure for complex cancer planning
- IRE / NanoKnife, cryosurgical ablation and argon-helium knife are described in official treatment and MDT materials
- Y-90 radioembolization, TACE, brachytherapy and photodynamic therapy are identified in official hospital content
- Chemotherapy, targeted therapy, immunotherapy, hyperthermia and TCM supportive oncology are referenced in the MDT service
- MDT consultation for digestive, thoracic, breast and gynecologic, head and neck, and urogenital tumors
- Minimally Invasive Oncology Center and Royallee–Boji Renyi Hepatobiliary and Pancreatic Oncology Department are listed in official materials
- ⚠️ VERIFY: CAR-NK, TIL and MCTL therapy need direct hospital confirmation for each patient because clear official verification was not found
- Laboratory Department and Pharmacy Department are listed as official hospital departments
- ICU, surgical anesthesia, laminar-flow operating rooms and a compound operating room are described in official profile material
- ⚠️ VERIFY: active clinical trials and specific genomics platforms were not published clearly on official English pages reviewed
International Patient Support at Royal Lee Cancer Center
Royal Lee Cancer Center publishes several services for patients traveling from outside China, including online second opinion, multilingual interpretation, appointment coordination, visa and travel support, airport transfers, accommodation support, and payment or insurance assistance. CancerFax helps patients prepare documents and coordinate these steps without acting as a hospital or treatment provider.
What to Prepare Before Traveling
- arrow_rightShare recent discharge summaries, pathology reports, immunohistochemistry, molecular testing, operative notes, chemotherapy or radiotherapy records, and current medication lists for pre-arrival review.
- arrow_rightUpload CT, MRI, PET-CT or other imaging in DICOM format when possible, because the MDT service asks for complete imaging data and reports for complex cases.
- arrow_rightConfirm the recommended department, estimated treatment plan, visa documents, expected length of stay, companion needs, and payment method before booking flights.
Patients may contact Royal Lee Cancer Center at +86-18613012387 or [email protected]; CancerFax can help prepare the medical file and coordinate communication so families understand the likely next steps before traveling to Guangzhou.
Patient Facilities and Accommodation at Royal Lee Cancer Center
Royal Lee Cancer Center’s official pages describe an oncology campus with inpatient wards, restaurants, parking, patient lounges, cafés, waiting areas, and multiple room categories designed for patients traveling with family. Nearby hotels and serviced apartments are listed by the hospital for families who prefer accommodation outside the ward.
Families traveling to Guangzhou should confirm whether they will stay in a hospital suite, nearby serviced apartment, or hotel before arrival, because room choice affects privacy, companion access, cost, and length-of-stay planning.
How to Reach Royal Lee Cancer Center
Royal Lee Cancer Center is located in Sino-Singapore Guangzhou Knowledge City in Huangpu District, Guangzhou. Official guidance identifies Guangzhou Baiyun International Airport as the nearest major airport, about 36 km away and roughly 30–40 minutes by car depending on traffic.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Royal Lee Cancer Center — Patient Questions Answered
CancerFax helps you organize medical records, imaging, pathology, prior treatment details, and current questions into a structured case file before submission. Based on your diagnosis and goals, CancerFax can help identify whether Royal Lee Cancer Center’s MDT, minimally invasive oncology, gastrointestinal, hepatobiliary-pancreatic, breast, gynecologic, palliative, or interventional services may be relevant for review.
After the hospital or relevant channel confirms next steps, CancerFax can help explain the appointment pathway, documents needed for travel, likely cost-estimate process, and communication timeline. CancerFax is a patient-navigation and coordination platform, not a hospital or treatment provider, and preliminary report review through CancerFax is offered without obligation.
Official pages emphasize solid tumors and MDT-led care, especially digestive system cancers such as stomach, colorectal, liver, bile duct and pancreatic cancers; thoracic tumors including lung and esophageal cancers; breast and gynecologic cancers; head and neck cancers; and urogenital cancers. Hematologic malignancies and pediatric oncology should be confirmed directly because they were not clearly described as core programs in the official English pages reviewed.
⚠️ VERIFY: The user-requested interest areas of CAR-NK, TIL and MCTL therapy were not clearly verified as routine Royal Lee Cancer Center capabilities on the official English pages reviewed. Official materials do mention immunotherapy and modern gene immunotherapy technology in MDT content, but eligibility, availability, trial status, regulatory pathway, and cost must be confirmed case by case before a patient travels.
Yes. Official pages describe a Second Opinion Consultation process that includes remote report upload, medical-record preparation, expert arrangement, formal consultation, written consultation report, report interpretation, follow-up, and support for treatment in China if the patient proceeds. The official MDT page states that, after complete records are submitted, a written opinion can normally be completed within 48 hours.
Official patient-service pages state that cost estimates distinguish examination fees, treatment fees, and hospitalization fees, while international-patient pages mention open treatment costs and payment or insurance support. Exact costs depend on diagnosis, imaging, pathology review, inpatient room type, medicines, procedure selection, and length of stay. CancerFax can help request and explain an estimate but does not add hospital markups.
Send Your Medical Reports to Royal Lee Cancer Center via CancerFax
If you are considering Royal Lee Cancer Center in Guangzhou, CancerFax can review your records, prepare a structured case summary, and coordinate consultation steps at no cost before you decide on travel.